Search results
Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
GuruFocus.com via Yahoo Finance· 8 hours agoThe company is still in the early stages of discussion with the FDA regarding the multi-dose expansion arm for their Phase 1 trial, indicating potential delays in trial progression ...
WHO clears Takeda's dengue vaccine
Reuters via AOL· 1 day agoThe approval, called a prequalification, comes amidst a surge in mosquito-borne viral infections across Asia, Africa, and the Americas, including new...
Saudi Arabia’s The Line Megadevelopment Gets A Lot Shorter
Dwell via Yahoo News· 59 minutes agoCourtesy NEOM Perhaps the video was an attempt at a dose of optimism to drum up greater investment...
J&J to buy Proteologix and its dual-targeting antibody drugs for $850M
BioPharma Dive via Yahoo Finance· 4 hours agoThe deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an...
Lumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ...
GuruFocus.com via Yahoo Finance· 8 hours agoResearch and development expenses increased by $2.9 million due to higher licensing and clinical trial expenses, adding financial pressure as the company progresses towards ...
Earnings call: Biora Therapeutics reports progress on NaviCap and BioJet platforms By Investing.com
Investing.com· 16 hours agoBiora Therapeutics (NASDAQ:BIOR) has announced significant advancements in its NaviCap and BioJet...
Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...
GuruFocus.com via Yahoo Finance· 8 hours agoNet Loss (Q1 2024): $37.2 million, or $0.63 per share. Net Loss (Q4 2023): $9.1 million, or $0.15 per share. Cash and Investments (As of March 31, 2024) ...
BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
GuruFocus.com via Yahoo Finance· 1 day agoExpected Operating Cash Burn: Approximately $20 million for Q2 2024, with a decrease anticipated in the second half of the year. Funding Operations: Current...and an 86% disease ...
Earnings call: Plus Therapeutics reveals Q1 2024 financials, clinical progress By Investing.com
Investing.com· 3 hours agoTherapeutics, Inc. (NASDAQ:PSTV) announced its first quarter 2024 financial results and provided...
Column: No Mow May should be 'No Spray May': Let's stop abusing Mother Earth
Gannett via AOL· 6 hours agoBut mowing isn’t the real issue; this month would be better called “No Spray May” as we need to stop...